Table 2.
Vaccine effectiveness against COVID-19-related outcomes and mortality amongst individuals with different vaccination status. VE: vaccine effectiveness; CI: confidence interval; REF: reference level; CVD: cardiovascular disease; B-B-C: two doses of BNT162b2 followed by CoronaVac; C—C-B: two doses of CoronaVac followed by BNT162b2; NA: Not available due to insufficient number; ICU: intensive care unit. Vaccine effectiveness was adjusted by HbA1c, comorbidities (hypertension, cancer, chronic kidney disease, respiratory disease, coronary heart disease, stroke, heart failure, dementia), chronic medication uses in the past 90 days (renin-angiotensin-system agents, beta-blockers, calcium channel blockers, diuretics, nitrates, lipid-lowering agents, oral anticoagulants, antiplatelets, immunosuppressants, oral anti-diabetic drugs, and insulin).
| Outcome | Unvaccinated | 1 dose only |
2 doses only |
3 doses |
|||||
|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 | CoronaVac | All BNT162b2 | All CoronaVac | All BNT162b2 | All CoronaVac | B-B-C | C-C-B | ||
| Infection | |||||||||
| Case | 16,707 | 2424 | 12,090 | 13,336 | 23,608 | 4339 | 7992 | 67 | 2024 |
| Control | 56,596 | 11,486 | 39,653 | 59,421 | 83,073 | 32,659 | 34,759 | 246 | 11,667 |
| VE% | REF | 27.8 | −7.3 | 22.1 | −0.3 | 54.2 | 19.8 | 12.1 | 39.9 |
| (95% CI) | (24.2 - 31.2) | (−10.3 - −4.4) | (20.0 - 24.2) | (−2.7 - 2.1) | (52.4 - 55.9) | (17.2 - 22.3) | (−15.8 - 33.3) | (36.6 - 42.9) | |
| Hospitalisation | |||||||||
| Case | 5122 | 310 | 2151 | 639 | 1633 | 109 | 229 | 0 | 48 |
| Control | 27,368 | 3207 | 15,891 | 12,645 | 24,968 | 6052 | 7975 | 44 | 2170 |
| VE% | REF | 51.0 | 24.4 | 74.2 | 64.2 | 91.4 | 85.4 | NA | 89.5 |
| (95% CI) | (44.5 - 56.8) | (19.9 - 28.7) | (71.7 - 76.4) | (61.8 - 66.4) | (89.5 - 92.9) | (83.2 - 87.3) | (85.9 - 92.2) | ||
| ICU admission or ventilatory support | |||||||||
| Case | 271 | 21 | 120 | 23 | 90 | 8 | 5 | 0 | 1 |
| Control | 1421 | 194 | 852 | 695 | 1266 | 310 | 385 | 2 | 127 |
| VE% | REF | 44.6 | 16.1 | 82.3 | 58.1 | 86.3 | 94.8 | NA | 95.9 |
| (95% CI) | (8.6 - 66.4) | (−7.9 - 34.7) | (72.1 - 88.8) | (45.0 - 68.1) | (71.5 - 93.4) | (85.8 - 98.1) | (70.3 - 99.4) | ||
| CVD | |||||||||
| Case | 46 | 2 | 27 | 16 | 30 | 2 | 10 | 0 | 2 |
| Control | 296 | 43 | 174 | 198 | 357 | 113 | 124 | 0 | 30 |
| VE% | REF | 69.4 | −3.1 | 50.3 | 48.4 | 90.9 | 46.3 | NA | 52.3 |
| (95% CI) | (−35.8 - 93.1) | (−77.5 - 40.1) | (5.1 - 73.9) | (10.8 - 70.2) | (60.2 - 97.9) | (−16.0 - 75.1) | (−116.6 - 89.5) | ||
| All-cause mortality | |||||||||
| Case | 1938 | 50 | 547 | 55 | 284 | 5 | 18 | 0 | 1 |
| Control | 8898 | 862 | 5092 | 2834 | 6640 | 1343 | 1911 | 18 | 458 |
| VE% | REF | 67.8 | 44.7 | 90.3 | 74.8 | 98.2 | 94.9 | NA | 98.7 |
| (95% CI) | (55.8 - 76.5) | (37.6 - 51.1) | (86.9 - 92.9) | (70.7 - 78.3) | (95.5 - 99.3) | (91.6 - 96.9) | (90.4 - 99.8) | ||